Shukra Pharmaceuticals balance sheet

As of Mar 2024
Total assets
₹77.8cr+3.8% on Mar 2023
Shareholders' equity
₹57.6cr+127.9% on Mar 2023
Total debt
₹2.7cr−47.7% on Mar 2023
Cash and investments
₹10.0cr+151.2% on Mar 2023
₹ crore except per share
Tap a line for its trendFY24Mar 2024FY23Mar 2023
Non-current assets
19.920.2
—1.7
Current assets
2.33.2
24.530.2
10.04.0
10.0—
2.02.3
17.113.2
77.875.0
Equity
10.93.9
46.721.4
57.625.3
Liabilities
—3.8
3.33.3
—0.1
2.71.3
7.234.3
5.66.9
77.875.0
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

SHUKRAPHAR₹71.92

Shukra Pharmaceuticals Limited

· Pharma & Health
₹ CrorePeersBPLPHARMAJENBURPHKPLMAKERSLNOVARTINDPARNAXLABSGRLSUNLOCMcap ₹58 Cr
View
In ₹ Crore except Per Share
As of
FY23
31/03/2023
FY24
31/03/2024
Non-current Assets
+ Property, Plant & Equipment20.219.9
+ Capital Work-in-Progress1.7—
Current Assets
+ Inventories3.22.3
+ Trade Receivables30.224.5
+ Cash & Cash Equivalents4.010.0
+ Other Bank Balances—10.0
+ Short-term Loans2.32.0
+ Other Current Assets13.217.1
Total Assets75.077.8
Equity
+ Equity Share Capital3.910.9
+ Other Equity / Reserves21.446.7
Total Equity25.357.6
Liabilities
+ Borrowings — Non-current3.8—
+ Deferred Tax Liabilities3.33.3
+ Other Non-current Liabilities0.1—
+ Borrowings — Current1.32.7
+ Trade Payables34.37.2
+ Other Current Liabilities6.95.6
Total Equity & Liabilities75.077.8
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY24 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.